Glenmark Pharmaceuticals informs about media release

16 Mar 2026 Evaluate

Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) announced about the upcoming launch1 of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. Glenmark’s Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832]. Glenmark will begin distribution in March 2026. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.


Glenmark Pharma Share Price

2181.05 82.75 (3.94%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×